Hailong Li, Jinhe Li, Jinhe Li, Ting Xiao, Yayue Hu, Yayue Hu, . . . Cheng Yang. (2022). Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways. Frontiers Media S.A..
Chicago Style (17th ed.) CitationHailong Li, et al. Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways. Frontiers Media S.A., 2022.
MLA (9th ed.) CitationHailong Li, et al. Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways. Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.